Abstract
The pH-centered treatment for cancer needs powerful help from anti-angiogenic schemes. The administration of low, uninterrupted doses of a chemotherapeutic drug associated with a non-steroidal anti-inflammatory compound, usually a selective COX2 inhibitor, has an antiangiogenic effect that usually achieves a stable disease, lasting approximately for 1 year. For reasons not fully clarified, resistance generally develops after a year and there is often an increase in metastasis. When pH reversion treatments are used in association with metronomic anti-angiogenesis there is a higher rate of response with synergistic effects against the tumor and a prolonged delay of resistance. The rate of metastasis, which seems to increase with metronomic antiangiogenesis as a stand-alone treatment was not found when it was associated with the pH reversal approach.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call